Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Allott, Emma H ^a,b   Geradts, Joseph ^c   Sun, Xuezheng ^b   Cohen, Stephanie M ^a   Zirpoli, Gary R ^d   Khoury, Thaer ^d   Bshara, Wiam ^d   Chen, Mengjie ^b,e   Sherman, Mark E ^f   Palmer, Julie R ^g   Ambrosone, Christine B ^d   Olshan, Andrew F ^a,b   Troester, Melissa A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g BOSTON UNIVERSITY   (United States)

Author keywords

Automated algorithm; Digital pathology; Discordance; Estrogen receptor; HER2; Immunohistochemistry; Intratumoral heterogeneity; Progesterone receptor; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ALGORITHM; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CLASSIFICATION; DIGITAL IMAGING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; TISSUE MICROARRAY; BIOPSY; BREAST NEOPLASMS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 84976340210     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0725-1     Document Type: Article

References (33)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. doi: 10.1038/35021093.
2. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, et al. Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. 2009;18(8):2214-20. doi: 10.1158/1055-9965.EPI-09-0301.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74. doi: 10.1073/pnas.191367098.
4. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst. 2008;100(3):218-21. doi: 10.1093/jnci/djm270.
5. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26(15):2473-81. doi: 10.1200/JCO.2007.13.6424.
6. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24(19):3032-8. doi: 10.1200/JCO.2005.03.4744.
7. Li S, Yang X, Zhang Y, Fan L, Zhang F, Chen L, et al. Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):325-34. doi: 10.1007/s10549-012-2063-z.
8. McCullough AE, Dell'Orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, et al. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat. 2014;143(3):485-92. doi: 10.1007/s10549-013-2827-0.
9. Chen X, Yuan Y, Gu Z, Shen K. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;134(3):957-67. doi: 10.1007/s10549-012-1990-z.
10. Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006;7(2):153-7. doi: 10.3816/CBC.2006.n.025.
11. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22(11):1457-67. doi: 10.1038/modpathol.2009.117.
12. Qiu J, Kulkarni S, Chandrasekhar R, Rees M, Hyde K, Wilding G, et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol. 2010;134(5):813-9. doi: 10.1309/AJCPVCX83JWMSBNO.
13. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest. 2007;87(7):662-9. doi: 10.1038/labinvest.3700543.
14. Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL. Loss of antigenicity with tissue age in breast cancer. Lab Invest. 2016;96(3):264-9. doi: 10.1038/labinvest.2015.138.
15. Greer LT, Rosman M, Mylander WC, Hooke J, Kovatich A, Sawyer K, et al. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg. 2013;216(2):239-51. doi: 10.1016/j.jamcollsurg.2012.09.007.
16. Palmer JR, Ambrosone CB, Olshan AF. A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium. Cancer Causes Control. 2014;25(3):309-19. doi: 10.1007/s10552-013-0332-8.
17. Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, et al. Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev. 2016;25(3):470-8. doi: 10.1158/1055-9965.EPI-15-0874.
18. Hair BY, Hayes S, Tse CK, Bell MB, Olshan AF. Racial differences in physical activity among breast cancer survivors: implications for breast cancer care. Cancer. 2014;120(14):2174-82. doi: 10.1002/cncr.28630.
19. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.
21. Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma: a comparison of eight contemporary grading systems. Am J Clin Pathol. 2001;115(5):709-18. doi: 10.1309/PJ7H-A52V-M3XB-V94Y.
22. Kobayashi M, Ooi A, Oda Y, Nakanishi I. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum Pathol. 2002;33(1):21-8.
23. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21-7.
24. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer. 2003;10(1):91-8. doi: 10.1677/erc.0.0100091.
25. Hodi Z, Chakrabarti J, Lee AH, Ronan JE, Elston CW, Cheung KL, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol. 2007;60(3):299-302. doi: 10.1136/jcp.2006.036665.
26. Douglas-Jones AG, Collett N, Morgan JM, Jasani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol. 2001;54(12):951-5.
27. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event. Breast J. 2007;13(2):122-9. doi: 10.1111/j.1524-4741.2007.00396.x.
28. Andersson J, Linderholm B, Bergh J, Elmberger G. HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol. 2004;12(1):14-20.
29. Glöckner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest. 2002;82(10):1419-26.
30. Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12(7):381-94. doi: 10.1038/nrclinonc.2015.73.
31. Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786-8. doi: 10.1172/JCI60534.
32. Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 2014;15(8):453. doi: 10.1186/s13059-014-0453-8.
33. Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, et al. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol Clin Res. 2015;1(1):18-32.